Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A

As of June 30, 2026, Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A carries a market capitalization of 6.43B, placing it among publicly traded companies globally. Its enterprise value stands at 6.89B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A has 611.69M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 6.74, and the price-to-book ratio stands at 2.50.

These figures are as of June 30, 2026. The EV/Sales ratio of 7.24 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.89B versus a market cap of 6.43B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A maintains a current ratio of 1.28, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A posted a negative return on equity (ROE) of -4.19, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.54, reflecting losses generated across the asset base. The company generates approximately 686,901.19 in revenue per employee across its workforce of 1,385.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.42 indicates how many times Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A recorded 13.96M in income tax expense. The company reported a pretax loss of -104.56M and -110.17M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A's stock has declined approximately 26.27% over the past 52 weeks. The 50-day moving average sits at 10.61, while the 200-day moving average is 15.73.

Over the twelve months ended June 30, 2026, Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A generated 951.87M in revenue and converted that into -110.17M in net income, yielding earnings per share of -0.19. EBITDA reached -98.13M, while operating income came in at -9.40M.

As of June 30, 2026, Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A holds 568.77M in cash and equivalents against 942.34M in total debt, resulting in a net debt position of 219.44M. Total book value stands at 2.58B, with working capital of 387.43M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A posted a gross margin of 42.80, reflecting its pricing power and cost economics. The operating margin of -0.99 and net profit margin of -11.57 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A paid dividends of 0.08 per share. The dividend payout ratio of -37.21 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.02, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A shareholders.

Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A's most recent stock split took place on June 10, 2008 with a 5:8 split ratio.

As of June 30, 2026, Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A has an Altman Z-Score of 3.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.